AstraZeneca To Launch Phase I Trial Of Liver Cancer Drug Developed In China
This article was originally published in PharmAsia News
An AstraZeneca drug said to be the first of its kind to be developed in China by a multinational drug maker is about to undergo clinical trials to see if it is effective for treating liver cancer. The disease is China's second-largest killer, lung cancer being first. China's State FDA has approved the Phase I clinical trial, a step somewhat unusual since China often relies on results from a first-stage abroad before approving one locally. The drug was developed through global chemistry research by the company's Chinese innovation center, its sole research facility in Asia. (Click here for more
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.